Emerging drugs for the treatment of basal cell carcinoma

Herms, F.; Basset-Séguin, Nicole

doi:10.1080/14728214.2021.1873949

Cited by 5 publications

(6 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Basal cell carcinoma (BCC) is one of the most common tumors of the skin and accounts for 75% of all skin cancer entities diagnosed in light‐skinned people. Increasing incidence rates of BCC have been recorded 1–3 …”

Section: Status Quo Of Bcc Therapymentioning

confidence: 99%

See 1 more Smart Citation

New therapeutic developments for basal cell carcinoma

Kunstfeld¹,

Nguyen

2023

J Deutsche Derma Gesell

View full text Add to dashboard Cite

SummaryIn 2013, systemic therapy was introduced into the treatment of locally advanced (laBCC) and metastatic basal cell carcinoma (mBCC). Meanwhile, immunotherapy has been approved in this indication as well. Additional immunotherapies and other classes of drugs including combination regimens are currently being investigated in clinical trials. These agents might considerably expand the therapeutic armamentarium for laBCC and mBCC in the future.

show abstract

Section: Status Quo Of Bcc Therapymentioning

confidence: 99%

“…Increasing incidence rates of BCC have been recorded. [1][2][3] Surgical excision is still the therapy of choice and is also the most effective therapy in case of R0 resection. [4][5][6] Excision is possible in > 95% of cases.…”

mentioning

confidence: 99%

New therapeutic developments for basal cell carcinoma

Kunstfeld¹,

Nguyen

2023

J Deutsche Derma Gesell

View full text Add to dashboard Cite

show abstract

“…Mit 75% aller bei hellhäutigen Menschen diagnostizierten Hautkrebsentitäten zählt das Basalzellkarzinom (BCC) zu den häufigsten Tumoren der Haut, wobei eine steigende Inzidenz zu verzeichnen ist. [1][2][3] Die chirurgische Entfernung ist nach wie vor die Therapie der Wahl und stellt bei R0-Resektion auch die effektivste Therapieform dar. [4][5][6] In mehr als > 95% der Fälle ist eine Exzision möglich.…”

Section: Status Quo In Der Therapie Von Bccunclassified

Neue Entwicklungen in der Behandlung des Basalzellkarzinoms

Kunstfeld

Nguyen

2023

J Deutsche Derma Gesell

View full text Add to dashboard Cite

ZusammenfassungIm Jahr 2013 hat die systemische Therapie Einzug in die Behandlung des lokal fortgeschrittenen (locally advanced, laBCC) und metastasierten Basalzellkarzinoms (mBCC) gefunden. Mittlerweile ist auch die Immuntherapie in dieser Indikation zugelassen. Weitere Immuntherapeutika und andere Substanzklassen – darunter auch Kombinationsstrategien – befinden sich gegenwärtig in klinischer Entwicklung beziehungsweise werden in klinischen Studien untersucht. Diese könnten zukünftig die Therapiemöglichkeiten bei laBCC und mBCC bedeutend erweitern.

show abstract

“…New approaches to BCC treatment have been advanced to meet patient needs. Intratumoral remedies, topical use of HH inhibitors, and neoadjuvant indications have been investigated [ 49 ].…”

Section: Available Therapiesmentioning

confidence: 99%

Basal Cell Carcinoma: Pathology, Current Clinical Treatment, and Potential Use of Lipid Nanoparticles

Łasińska

Zielińska

Mackiewicz

et al. 2022

Cancers

View full text Add to dashboard Cite

Skin cancer is the most common type of carcinoma diagnosed worldwide, with significant morbidity and mortality rates among Caucasians, in particular basal cell carcinoma (BCC). The main risk factors of BCC are well-identified, and there are many chemotherapeutic drugs available for its treatment. The effectiveness of therapeutic options is governed by several factors, including the location of the tumor, its size, and the presence of metastases (although rare for BCC). However, available treatments are based on non-targeted approaches, which encounter a significant risk of systemic toxicity in several organs. Site-specific chemotherapy for BCC has been proposed via the loading of anticancer drugs into nanoparticles. Among various types of nanoparticles, in this review, we focus on potential new regimens for the treatment of BCC using classical anticancer drugs loaded into novel lipid nanoparticles. To meet patient aesthetic expectations and enhance the effectiveness of basal cell carcinoma treatment, new therapeutic topical strategies are discussed, despite a limited number of reports available in the literature.

show abstract

Emerging drugs for the treatment of basal cell carcinoma

Cited by 5 publications

References 44 publications

New therapeutic developments for basal cell carcinoma

New therapeutic developments for basal cell carcinoma

Neue Entwicklungen in der Behandlung des Basalzellkarzinoms

Basal Cell Carcinoma: Pathology, Current Clinical Treatment, and Potential Use of Lipid Nanoparticles

Contact Info

Product

Resources

About